HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toshiyuki Tomoo Selected Research

3- (1- (4- phenoxyphenyl)- 3- (2- phenylethyl)- 1H- indol- 5- yl)propanoic acid

3/2016ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toshiyuki Tomoo Research Topics

Disease

1Heart Failure
01/2017
1Non-alcoholic Fatty Liver Disease
03/2016
1Fatty Liver
03/2016
1Fibrosis (Cirrhosis)
03/2016
1Inflammation (Inflammations)
03/2016
1Glioblastoma (Glioblastoma Multiforme)
02/2016
1Glioma (Gliomas)
02/2016
1Neoplasms (Cancer)
02/2016
1Edema (Dropsy)
09/2014
1Asthma (Bronchial Asthma)
09/2014

Drug/Important Bio-Agent (IBA)

1CholesterolIBA
03/2016
1LipidsIBA
03/2016
1PropaneIBA
03/2016
1PropionatesIBA
03/2016
1SaltsIBA
03/2016
1Group IV Phospholipases A2IBA
03/2016
13- (1- (4- phenoxyphenyl)- 3- (2- phenylethyl)- 1H- indol- 5- yl)propanoic acidIBA
03/2016
1Carbon Tetrachloride (Tetrachloromethane)IBA
03/2016
1Liposomes (Liposome)IBA
02/2016
1Class 5 Receptor-Like Protein Tyrosine PhosphatasesIBA
02/2016
1OvalbuminIBA
09/2014
1phorbolIBA
09/2014
1Acetates (Acetic Acid Esters)FDA Link
09/2014

Therapy/Procedure

2Therapeutics
01/2017 - 02/2016